Tackling hard to treat lung cancers
About Dean Fennell
Professor Dean Fennell is a leading specialist in lung cancer and heads the lung cancer research programme at the University of Leicester. He is an expert in testing new treatments for people with the disease.
Professor Fennell is running a clinical trial called MESO 2, testing whether adding a drug called vorinostat to chemotherapy benefits people with a type of lung cancer called mesothelioma, which is usually caused by exposure to asbestos. Mesothelioma is normally treated with chemotherapy to slow the growth of the cancer, but more effective options are urgently needed to improve survival for people with this disease.
Another important trial, called PIN, is testing a new treatment for people with non-small cell lung cancer. The drug, olaparib, is a targeted treatment that was developed by Cancer Research UK scientists. Professor Fennell is finding out whether olaparib makes chemotherapy more effective at killing cancer cells in people with non-small cell lung cancer who have mistakes in their BRCA1 gene.
He’s also involved with Tracer X, a landmark Cancer Research UK-funded project tracking how lung cancers change over time and become resistant to treatment.
Lung cancer is the second most common cancer in the UK, claiming tens of thousands of lives every year in the UK. Improving survival from lung cancer is one of our key priorities, and clinical trials like Professor Fennell’s are urgently needed to bring new treatments to people with this disease.
Other research projects by Dean Fennell
CRUKE/09/025: MESO-2: A first line randomised phase I/II trial of pemetrexed and cisplatin with or without the Heatshock Protein 90 inhibitor Ganetespib in patients with malignant pleural mesothelioma
CRUK/12/056: VIM - A randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma
Funding period: 01 August 2013 to 31 July 2018